萬德斯(688178.SH):創投二期、寧泰創投擬減持不超3%的股份
格隆匯3月3日丨萬德斯(688178.SH)公佈,根據自身業務需要,創投二期、寧泰創投遵照《上海證券交易所上市公司創業投資基金股東減持股份實施細則》的要求,適用於如下規定:截至首次公開發行上市日,投資期限在36個月以上但不滿48個月的,在任意連續60日內減持股份的總數不得超過公司股份總數的1%。創投二期、寧泰創投計劃在履行減持股份預先披露義務的十五個交易日後的六個月內,通過集中競價方式減持公司股份合計不超過公司股份總數的3%(即254.9935萬股)。減持價格按照市場價格確定,且不低於發行人股票的發行價。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.